Cyclerion Therapeutics, Inc. (CYCN)
NASDAQ: CYCN · Real-Time Price · USD
3.190
+0.240 (8.14%)
At close: Dec 20, 2024, 4:00 PM
3.400
+0.210 (6.58%)
After-hours: Dec 20, 2024, 6:17 PM EST
Cyclerion Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 0.19 | - | 0.3 | 3.94 | 2.3 | 4.51 | |
| Revenue Growth (YoY) | - | - | -92.47% | 71.69% | -49.06% | - | |
| Cost of Revenue | 1.32 | 1.32 | 5.58 | 37.64 | 56.41 | 95.14 | |
| Gross Profit | -1.12 | -1.32 | -5.28 | -33.69 | -54.12 | -90.63 | |
| Selling, General & Admin | 6.07 | 8.33 | 13.26 | 20.62 | 28.82 | 34.4 | |
| Research & Development | -1.26 | - | - | - | - | - | |
| Operating Expenses | 4.8 | 8.33 | 13.26 | 20.62 | 28.82 | 34.4 | |
| Operating Income | -5.93 | -9.65 | -18.54 | -54.31 | -82.93 | -125.04 | |
| Interest Expense | - | - | - | -0.02 | - | - | |
| Interest & Investment Income | 0.28 | 0.36 | 0.29 | - | 0.3 | 1.9 | |
| Other Non Operating Income (Expenses) | 0.36 | - | - | - | 0.29 | 0.13 | |
| EBT Excluding Unusual Items | -5.28 | -9.29 | -18.25 | -54.33 | -82.35 | -123.01 | |
| Asset Writedown | - | -3.3 | - | - | - | - | |
| Other Unusual Items | - | - | - | 2.68 | 4.54 | - | |
| Pretax Income | -5.28 | -12.59 | -18.25 | -51.65 | -77.8 | -123.01 | |
| Earnings From Continuing Operations | -5.28 | -12.59 | -18.25 | -51.65 | -77.8 | -123.01 | |
| Earnings From Discontinued Operations | - | 7.33 | -25.83 | - | - | - | |
| Net Income | -5.28 | -5.26 | -44.08 | -51.65 | -77.8 | -123.01 | |
| Net Income to Common | -5.28 | -5.26 | -44.08 | -51.65 | -77.8 | -123.01 | |
| Shares Outstanding (Basic) | 2 | 2 | 2 | 2 | 2 | 1 | |
| Shares Outstanding (Diluted) | 2 | 2 | 2 | 2 | 2 | 1 | |
| Shares Change (YoY) | 10.09% | 7.59% | 11.03% | 28.75% | 11.04% | - | |
| EPS (Basic) | -2.12 | -2.25 | -20.28 | -26.39 | -51.18 | -89.85 | |
| EPS (Diluted) | -2.12 | -2.25 | -20.28 | -26.39 | -51.18 | -89.85 | |
| Free Cash Flow | -6.23 | -21.25 | -40.61 | -36.52 | -74.01 | -109.1 | |
| Free Cash Flow Per Share | -2.50 | -9.09 | -18.69 | -18.66 | -48.69 | -79.70 | |
| Operating Margin | -3054.12% | - | -6242.42% | -1377.83% | -3612.11% | -2774.28% | |
| Profit Margin | -2722.16% | - | -14841.08% | -1310.17% | -3388.59% | -2729.27% | |
| Free Cash Flow Margin | -3213.40% | - | -13673.74% | -926.53% | -3223.61% | -2420.75% | |
| EBITDA | - | -9.58 | -18.48 | -53.84 | -80.64 | -122.34 | |
| D&A For EBITDA | - | 0.07 | 0.07 | 0.47 | 2.3 | 2.7 | |
| EBIT | -5.93 | -9.65 | -18.54 | -54.31 | -82.93 | -125.04 | |
| Revenue as Reported | 0.19 | - | 0.3 | 3.94 | 2.3 | - | |
Source: S&P Capital IQ. Standard template.
Financial Sources.